operations for 2nd Quarter of 2017 decreased to 71.69%, while it was 74.38% for the 2nd Quarter of 2016. These resulted from the efficiency of medicine and medical supplies cost management, introducing an
efficiency to the company’s operation . The Extraordinary of Shareholders’ Meeting will be hold in December 2017 to approve the transfer and closing of business. The process of this transaction will be
property, plant and equipment acquired for the new factory (Phase 3) and for the Efficiency improvement at the subsidiaries. Total Liabilities Total liabilities decreased from Bt7,300 million at the end of
to the improvement in cost efficiency. 4. Finance cost was Baht 447.68 million, a decrease of Baht 56.00 million or down by 11.12%, due to the lower cost of debt from refinancing bond issued in the
directors and containing at least details as specified in the provisions under Clause 8. The policy shall be reviewed on its efficiency and appropriateness at least once a year or promptly upon occurrence of
directors and containing at least details as specified in the provisions under Clause 8. The policy shall be reviewed on its efficiency and appropriateness at least once a year or promptly upon occurrence of
depreciation caused by the investment in machinery to improve production efficiency, reduce cost of production in the future, and support more sales volume in the future. - Administrative expenses increased by
customer base while also preparing to accommodate new clients this year. Moreover, there was an additional depreciation calculated by the investment in assets used in production to boost efficiency and
additional depreciation calculated by the investment in assets used in production to boost efficiency and reduce production costs in the long run. - Net profit according to the financial statement decreased by
boost efficiency and reduce production costs in the long run. - Net profit according to the financial statement decreased by Baht 16.45 million, in Q2’22; and increased by Baht 1.73 million, in the six